Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel
NASDAQ:NBTX

Nanobiotix 2/15/2026 Earnings Report

Nanobiotix logo
$34.77 +3.61 (+11.59%)
Closing price 04:00 PM Eastern
Extended Trading
$34.38 -0.40 (-1.14%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nanobiotix EPS Results

Actual EPS
-$0.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanobiotix Revenue Results

Actual Revenue
$3.42 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanobiotix Announcement Details

Quarter
Date
2/15/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nanobiotix Earnings Headlines

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
May 4 at 5:29 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3287230/0/en/nanobiotix-announces-protocol-amendment-to-ongoing-global-phase-3-head-and-neck-cancer-study.html
Nanobiotix Unveils Preclinical Data Showing Nanoprimer Boosts LNP-DNA Cancer Immunotherapy
April 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1418441/nanobiotix-unveils-preclinical-data-showing-nanoprimer-boosts-lnp-dna-cancer-immunotherapy/
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
May 5 at 1:00 AM  |  Brownstone Research (Ad)
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With ...
April 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/nanobiotix-announces-preclinical-data-supporting-063000390.html
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3276718/0/en/nanobiotix-announces-new-preclinical-data-supporting-improved-systemic-bioavailability-and-reduced-toxicity-for-lnp-delivered-dna-immunotherapy-after-pre-treatment-with-nanoprimer-.html
Nanobiotix SA - Depositary receipt (NBTX) price target increased by 26.60% to 34.52
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/nanobiotix-sa-depositary-receipt-nbtx-price-target-increased-by-2660-to-3452/ar-AA20uKW8
See More Nanobiotix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanobiotix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanobiotix and other key companies, straight to your email.

About Nanobiotix

Nanobiotix (NASDAQ:NBTX) is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma. The company is actively expanding its global footprint with ongoing trials in the United States, Asia, and other regions. Partnerships and collaborations with academic institutions and pharmaceutical companies support the clinical development and potential commercialization of its lead candidate. In addition to NBTXR3, Nanobiotix continues to explore next-generation nanotherapies and combination strategies aimed at enhancing standard oncology protocols.

Founded in 2003 by Dr. Laurent Levy and a team of researchers, Nanobiotix combines expertise in physics, chemistry and oncology to address unmet needs in cancer care. The company maintains R&D facilities in Europe and the United States and is led by Dr. Levy, who serves as Chief Executive Officer. Through its science-driven approach, Nanobiotix seeks to deliver safer, more effective treatment options for patients worldwide and to transform the way radiotherapy is applied in solid tumor oncology.

View Nanobiotix Profile
Earnings Tools